Abstract: A tamper-resistant pharmaceutical dosage form comprising a pharmacologically active ingredient embedded in a prolonged release matrix, which comprises a prolonged release matrix material selected from the group consisting of nonionic acrylic polymers and waxy materials and which provides prolonged release of the pharmacologically active ingredient, resistance against solvent extraction, resistance against grinding, and resistance against dose-dumping in aqueous ethanol.

Abstract: Therapeutic compositions comprising an indoloquinone compound and various bladder cancer treatments and methods are disclosed. More specifically, the compositions comprise an indoloquinone compound and a formulation vehicle. The formulation vehicle improves the solubility and stability of the indoloquinone compound. Additionally, the coating compositions can include coating agents that provide better adhesion of the coating composition to the bladder wall during intravesical delivery of the coating composition.

Abstract: A whole impregnated freeze dried food product for delivering a material of interest comprising; a. moisture content of less than about 5%; b. a material of interest; and, c. taste additives; wherein, the food product is maintained in it's whole original structure, volume and shape; further wherein the food product is functionally impregnated with the material of interest in an amount equivalent to the removed moisture residual, and methods for obtaining same.

Abstract: Compositions containing a drug to be delivered and at least one chemical permeation enhancer (CPE), and methods of making and using these compositions are described herein. In a preferred embodiment, the compositions contain two or more CPEs which behave in synergy to increase the permeability of the epithelium, while providing an acceptably low level of cytotoxicity to the cells. The concentration of the one or more CPEs is selected to provide the greatest amount of overall potential (OP). Additionally, the CPEs are selected based on the treatment. CPEs that behave primarily by transcellular transport are preferred for delivering drugs into epithelial cells. CPEs that behave primarily by paracellular transport are preferred for delivering drugs through epithelial cells. Also provided herein are mucoadhesive oral dosage forms. In a preferred embodiment, the oral dosage form is a multi-compartmental device, containing (i) a supporting compartment, (ii) drug compartment and (iii) mucoadhesive compartment.

Abstract: The invention provides novel pharmaceutical compositions based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble and/or hydrolytically sensitive drug substances. The compositions are designed as suspensions and have superior physical properties which make them highly useful as pharmaceutical delivery systems. The compositions may be administered topically into the eye, or injected via the subcutaneous or intramuscular route. The invention further provides kits comprising such compositions.

Abstract: An antimicrobial composition, generally comprising a biocidal agent, such as chlorhexidine gluconate, a lubricant, such as a modified siloxane, and a solvent, such as an alcohol and/or water. The biocidal agent acts as a highly effective biocide while the lubricant reduces friction between various components of a medical device during assembly. The antimicrobial composition may be applied to an internal component of the medical device prior to assembly. The process of assembling the medical device results in antimicrobial composition being distributed to various internal structures and geometries of the medical device as the coated, internal component is assembled into the interior of the medical device. Air is then used to further distribute excess antimicrobial agent to the remaining surfaces downstream from the installed, internal component. In some embodiments, additional air is passed through the assembled medical device to assist in removing the carrier solvent from the medical device via evaporation.

Abstract: Particles containing at least two incompatible materials, such as a hydrophilic agent and a lipophilic agent, and particles from gas saturated solution (PGSS) processes for making such particles are provided.

Abstract: A cosmetic composition in the form of an oil-in-water emulsion methods of using and producing cosmetic compositions is provided. The cosmetic composition includes an aqueous phase, an oil phase comprising a water-in-oil emulsifier, and an oil stabilizing component. The water-in-oil emulsifier is at concentration, by weight, of about 0.01% to about 6.0%, based upon weight of the composition. The oil stabilizing component includes one or both of an amphiphilic compound or a surfactant having an HLB of 13 or greater added to the aqueous phase. The oil stabilizing component is at a concentration, by weight, of about 0.01% to about 1.0%, based upon weight of the composition. The oil-in-water emulsion has an increased water load relative to water-in-oil emulsions without having an increased viscosity.

Abstract: The invention relates to a glycerol ether mixture which consists essentially of a) at least one C12-22 glycerol monoalkyl ether, b) at least one C12-22 glycerol dialkylether and optionally c) at least one C12-22 glycerol trialkyl ether and/or d) at least one C12-22 fatty alcohol, components a) and b) together making up at least 50% by weight of the glycerol ether mixture and the ratio by weight of component a) to component b) being in the range from 3:1 to 1:2. The invention also relates to a process for producing the glycerol ether mixture and to cosmetic compositions containing the glycerol ether mixture.

Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

Abstract: Described herein are cyclodextrin-stabilized microemulsion systems useful for increasing the solubility, stability, bioavailability, or safety of an active agent for delivery to the skin. The microemulsions may reduce the occurrence of skin irritation or odor upon application. In certain embodiments, the active agent is substantially insoluble in water. The microemulsions may be formulated as semi-solids, for example creams, or as aerosol or non-aerosol foams. Also described are methods of treating skin disorders, comprising the step of applying to an affected area of a subject in need thereof a therapeutically-effective amount of an inventive microemulsion.

Abstract: The present invention relates to processes for the recovery of ethanol from a crude ethanol product obtained from the hydrogenation of a mixed oxygenate stream comprising ethyl acetate and acetaldehyde. The crude ethanol product is separated in at least one distillation column to product ethanol. The mixed oxygenate stream may be obtained from syngas.

Abstract: Process for preparing 4-cyclohexyl-2-methyl-2-butanol The present invention relates to a process for preparing 4-cyclohexyl-2-methyl-2-butanol. The process comprises the following steps: a) reaction of styrene with isopropanol at elevated temperature to obtain 4-phenyl-2-methyl-2-butanol, and b) heterogeneously catalyzed hydrogenation of 4-phenyl-2-methyl-2-butanol over a catalyst suitable for ring hydrogenation of aromatics.

Abstract: Compounds and methods of using of compounds or mixtures thereof, as fragrance and/or flavoring material or as fragrance and/or flavoring material mixture, new fragrance and/or flavoring material mixtures, new perfumed and/or flavored articles, and new, particularly advantageous compounds and mixtures to be used are described.

Abstract: Embodiments claimed and claimed herein include anhydrous cosmetic composition embodiments. The anhydrous cosmetic composition embodiments include coconut alkanes comprising a volatile oily composition having from 50 to 100% by weight of a mixture of linear paraffins that include 70 to 99% by weight of at least one linear paraffin selected from C %, C10, C12 paraffins and mixtures thereof. The composition also includes a coconut gel comprising vegetable oil, Cocos Nucifera Oil, a styrene/butadiene copolymer and polyethylene. The composition embodiments also include polyethylene, caprylyl glycol, and a mixture of Acacia Decurrens/Jojoba/Sunflower Seed wax/Polyglyceryl 3-ester in concentrations effective for ensuring coconut alkanes are melted and homogeneous; and one or more anhydrous actives.

Abstract: Alkoxylation products, their preparation, compositions comprising these alkoxylation products, and the use thereof as or for producing adhesives and sealants.

Abstract: A biobeneficial coating composition for coating an implantable device, such as a drug eluting stent, a method of coating the device with the composition, and an implantable device coated with the composition are provided.

Abstract: The present invention relates to the use as a preserving agent, in particular in cosmetic or dermatological composition, of at least one compound of formula (I): in which:—X represents ?O or —OH;—R1 represents a hydrogen atom or a methyl;—R2 represents a hydrogen atom, a methyl or an ethyl;—R3 represents a C1-C12, saturated or unsaturated, linear hydrocarbon-based radical, optionally substituted with a hydroxyl group (OH); with the exclusion of the compound of formula (I) in which X represents ?O, R1=methyl, R2=H and R3=—(CH2)6—CH3. The invention also relates to certain novel compounds and to the cosmetic or dermatological compositions comprising same.

Abstract: An azeotrope-like mixture consisting essentially of chlorotrifluoropropene and at least one component selected from the group consisting of a C1-C3 alcohol, a C5-C6 hydrocarbon, a halogenated hydrocarbon, methylal, methyl acetone, water, nitromethane, and combinations thereof.

Abstract: The present invention relates to a fragrance composition comprising a mixture of diastereomers of 2-isobutyl-4-methyl-tetrahydro-2H-pyran-4-ol, which comprises more than 95 wt. % of the optically inactive cis-racemate and less than 5 wt. % of the optically inactive trans-racemate. The present invention further relates to a method for producing a perfumed product or article as well as perfumed or aromatized articles comprising the fragrance compositions of the present invention.

Abstract: The present invention provides micelles having an anthracycline encapsulated therein, the micelles comprising a multiblock copolymer. The invention further provides methods of preparing and using said micelles, and compositions thereof.

Abstract: Amphiphilic silicons which are dispersible or self-dispersing in water, have a high refractive index, and are prepared by a hydrosilylation reaction, resulting in products which are free of cyclic organopolysiloxanes. The high refractive index and dispersibility make the amphiphilic silicones useful in personal care and cosmetics where high shine or gloss is desired.

Abstract: The present invention provides micelles having an anthracycline encapsulated therein, the micelles comprising a multiblock copolymer. The invention further provides methods of preparing and using said micelles, and compositions thereof.

Abstract: What is described herein are antimicrobial compositions which are defined blends of a 1,2-diol and phenoxyethanol which show broad activity against bacteria, fungi and mold spores. This activity is potentiated by the addition thereto of small amounts of a co-biocide for which the blend acts as a delivery system for the otherwise water-insoluble co-biocide.

Abstract: The present invention is directed towards a process for making oral compositions comprising gel networks. The gel networks are formed from a fatty amphiphile dispersion and swelling surfactant. The fatty amphiphile dispersion comprises one or more fatty amphiphiles, one or more dispersing surfactants, and one or more solvents. A gel network is formed when the fatty amphiphile dispersion is combined with the swelling surfactant. A method of preparing the fatty amphiphile dispersion and oral composition is included.

Abstract: Drug formulations, devices and methods are provided to deliver biologically active substances to the eye. The formulations are delivered into scleral tissues adjacent to or into the suprachoroidal space without damage to the underlying choroid. One class of formulations is provided wherein the formulation is localized in the suprachoroidal space near the region into which it is administered. Another class of formulations is provided wherein the formulation can migrate to another region of the suprachoroidal space, thus allowing an injection in the anterior region of the eye in order to treat the posterior region.

Abstract: Mixtures of Guerbet alcohols, their use in cosmetic and/or pharmaceutical preparations, and also cosmetic and/or pharmaceutical preparations comprising mixtures of Guerbet alcohols are described. Of suitability as petroleum jelly substitute are in particular Guerbet alcohol mixtures with a melting range, measured by differential scanning calorimetry (DSC), between ?20° C. and +70° C., where the width of the melting range comprises at least 30 temperature degrees and the maximum of the melting range is 35±10° C. These are obtainable for example by reacting a) 55 to 95% by weight of cetylstearyl alcohol, b) 5 to 45% by weight of fatty alcohols with a chain length of from 8 to 22 carbon atoms and c) optionally an aliphatic diol having at least 3 carbon atoms.

Abstract: Disclosed are: a substance transfer carrier to an extracellular matrix-producing cell in the lung, which comprises a retinoid; a therapeutic agent for fibroid lung, which utilized the carrier; and a preparation kit of the therapeutic agent.

Abstract: Described herein are mixed ethers and cosmetic and/or pharmaceutical preparations comprising mixed ethers. Certain mixed ethers have a melting range between ?25° C. and +70° C., wherein the width of the melting range comprises at least 30 temperature degrees and the maximum of the melting range is 35±10° C. These mixed ethers are obtainable for example by condensation reaction of a) 25 to 90% by weight of unbranched fatty alcohols with a chain length of 12 to 18 carbon atoms; b) 5 to 50% by weight of isostearyl alcohol; c) 0 to 35% by weight of a fatty alcohol with a chain length of 20 and/or 22 carbon atoms; and d) 0 to 25% by weight of a fatty alcohol having 8 and/or 10 carbon atoms.

Abstract: A delivery system using materials that form a liquogel or nanocarrier are described. The delivery system comprises hyperbranched polyglycerols (HPGs). The delivery system can include a drug or therapeutic agent and this system can be used to administer the drug or therapeutic agent locally. The delivery system provides for controlled release of the drug or therapeutic agent.

Abstract: The present invention relates to self-assembling membranes. In particular, the present invention provides self-assembling membranes configured for securing and/or delivering bioactive agents. In some embodiments, the self-assembling membranes are used in the treatment of diseases, and related methods (e.g., diagnostic methods, research methods, drug screening).

Abstract: The present invention concerns an oil-in-water emulsion wherein the oil droplets of a diameter in the range of 5 nm to hundreds of micrometers exhibit a nano-sized self-assembled structurization with hydrophilic domains having a diameter size in the range of 0.5 to 200 nm, due to the presence of a lipophilic additive and the oil-in-water emulsion contains an active element being present in the range comprised between 0.00001 and 79% based on the total composition.

Abstract: The present invention provides a co-modified organopolysiloxane having a specified chemical structure in which a sugar alcohol-modified group and a silylalkyl group having a siloxane dendron structure, and optionally a long-chain hydrocarbon group are present. The co-modified organopolysiloxane is blended, as a surfactant, a powder treatment agent, a gelling agent or the like, or as a cosmetic raw material together with powder (s), oil agent (s) or the like, in a preparation for external use, and in particular, a cosmetic.

Abstract: Disclosed herein is preferably a multi-dose type non-aqueous oily injectable formulation including; an active ingredient (drug) expressing therapeutic effects, which is dissolved, dispersed or suspended in a therapeutically effective amount, in oil. The disclosed non-aqueous oily injectable formulation may include; an oil-affinitive preservative, and a hydrophilic excipient non-phase separable from the oil-affinitive preservative when the excipient is mixed with the oil-affinitive preservative.

Abstract: Methods for enhancing a preference for a product by repetitive use. The method involves formulating a perfume composition into a product, the perfume composition including (I) allyl caproate and (II) ambroxan or geranium oil.

Abstract: Methods for solubilizing carbon nanohorns and applications thereof, including the manufacture of composites, hydrogen storage, catalyst supports and drug delivery. In certain embodiments, the method can include: a) Reduction of pristine carbon nanohorns by an alkali metal to lead to a carbon nanohorn alkali salt; and b) Exposure of said carbon nanohorn alkali salt to a polar aprotic solvent to lead to a solution of reduced carbon nanohorns. In certain other embodiments, solutions of carbon nanohorns, and individual carbon nanohorns are obtainable by the methods, as well as uses of such individual carbon nanohorns and solutions of carbon nanohorns.

Abstract: A method for preparing a composition including a compound including vanillin and ethylvanillin is described. Also described, is a method of preparing a composition including a compound including vanillin and ethylvanillin according to a vanillin/ethylvanillin molar ratio of 2. The method can include an operation of co-granulating vanillin and ethylvanillin at a temperature of 50° C. to 57° C. in the form of a powder and in amounts such that the vanillin/ethylvanillin molar ratio is at least equal to 2, and an operation of lowering the temperature of the composition thus obtained to room temperature.

Abstract: Compositions, comprising menthofuran and selected menthol compounds which feature improved flavour and odour properties, are provided and, in addition, the production of compositions, specifically, of emulsions with an improved storage stability.

Abstract: The invention relates to stable oleaginous cosmetic or therapeutic foam compositions containing certain active agents, having unique therapeutic properties and methods of treatment using such compositions. The foamable composition includes at least one solvent selected from a hydrophobic solvent, a silicone oil, an emollient, a co-solvent, and mixtures thereof, wherein the solvent is present at a concentration of about 70% to about 96.5% by weight of the total composition, at least a non-ionic surface-active agent at a concentration of about 0.1% to less than about 10% by weight of the total composition; at least one gelling agent at a concentration of about 0.1% to about 5% by weight of the total composition; a therapeutically effective amount of at least one active agent; and at least one liquefied or compressed gas propellant, at a concentration of about 3% to about 25% by weight of the total composition.

Abstract: The present invention provides the efficacy-enhancing agent composition for an agricultural chemical containing at least one compound (A) selected from specific ethoxylate compounds, specific polyoxyethylene fatty acid esters, specific polyoxyethylene sorbitan fatty acid esters, specific (poly)glycerol fatty acid esters, and specific alkyl saccharides; and at least one compound (B) selected from specific polyoxyalkylene alkyl ethers and specific aliphatic alcohols.

Abstract: Methods and apparatuses for delivery of biologically active material and/or sensors to a target organ or system. The apparatuses allow for specific, controlled delivery of the biologically active material and targeted placement of sensors. The apparatuses may be fabricated from cellular and/or acellular biological active components to promote integration of sensors into tissue and achieve appropriate release of biologically active molecules. The apparatuses may be fabricated from plasma-containing materials or other biopolymers such that the apparatus will resorbed into the tissue following insertion. The biologically active cellular or acellular component may be incorporated into that material may then serve as the source of the therapeutic biologically active component. The apparatus may take the form of a screw, though numerous shapes arc contemplated.

Abstract: Described are coating systems for the controlled delivery of hydrophilic bioactive agents, for example, from implantable medical devices. The coating systems of the invention comprise (a) a polymeric basecoat layer containing one or more hydrophilic bioactive agents; and (b) an elution-controlling topcoat layer that comprises a poly(ethylene-co-vinyl acetate) copolymer. The elution rate of the hydrophilic bioactive agent can be controlled by varying the vinyl acetate concentration in the elution-controlling topcoat layer.

Abstract: Methods and compositions for treating central nervous system diseases and disorders are disclosed.

Abstract: Disclosed is 1) a method for greatly increasing the solubility of useful actives in siloxane matrix-forming preparations, and 2) the associated preparations, themselves. Volatilizing coagents are utilized to give novel gels containing heretofore siloxane-insoluble additives.

Abstract: A pharmaceutical or cosmetic carrier or composition for topical application characterized by rheological properties which render the carrier or composition semi-solid at rest and a liquid upon application of shear forces thereto. The composition or carrier are prepared by mixing 1-25 percent of a solidifying agent and 75-99 percent of a hydrophobic solvent, by weight, wherein at least one of them has therapeutic or cosmetic benefits, in the presence or absence of a biologically active substance.

Abstract: Sandalwood perfuming ingredients that are 2-[perhydro-trialkyl-2-naphthalenylidene]-1-propanol or propanal derivatives of the formula wherein one dotted line represents a carbon-carbon single bond and the other a carbon-carbon single bond or double bond; X represents a CH2OH group or a CHO group; each R1 represents a hydrogen atom or a methyl group; and the R2, taken separately, represent each a hydrogen atom or the two R2 groups, taken together, represent a CH2 group or a carbon-carbon double bond; and said compound is in the form of any one of its stereoisomers or a mixture thereof, along with the use of such compound(s) in perfuming compositions or articles in the perfumery industry.

Abstract: Disclosed is a stellate cell-specific drug carrier comprising a stellate cell-specific amount of a retinoid derivative and/or a vitamin A analogue, and a drug carrier component other than the retinoid derivative and/or a vitamin A analogue. Also disclosed in a medicine comprising the stellate cell-specific drug carrier, and a drug in an amount effective for controlling the activity or growth of stellate cells.

Abstract: A personal care composition contains at least one personal care component and at least one end-functionalized ionic silicone.

Abstract: Agrochemical concentrates having a continuous water-containing single phase, where said continuous phase also comprises an oil-based adjuvant and a hydrotrope capable of solubilising said adjuvant in said continuous phase, a process for making these concentrates and a method of using these concentrates.

Abstract: The present invention relates to a novel decenal mixture and the incorporation and use of this mixture as a fragrance material. The novel decenal mixture contains decenals that are represented by the formula set forth below: wherein the broken line represents one double bond and two single bonds.